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Imaging fusion
To The ediTor: We are interested in the technique noted by Kocer et al. 1 Endovascular intervention is a critical procedure for the treatment of intracranial vascular lesions requiring contrast medium to guide the vascular road map. Kocer et al. 1 used an imaging fusion technique in combination with MR angiography (MRA) and 2D fluoroscopic visualization for endovascular intracranial neuronavigation in the management of an internal carotid artery cavernous aneurysm with a stent. They demonstrated that the imaging fusion technique successfully reduced the use of the contrast agent, avoiding the potential risk of renal impairment.
We fully agree with their opinion. Actually, this imaging fusion technique provided not only a reduction in contrast use, but also minimized the exposure of radiation to doctors and staff. Moreover, the technique has great potential in application to embolization of arteriovenous malformations (AVMs). Furthermore, it could be applied to aid confidently in the recognition of the feeding artery in microneurosurgery for resection of an AVM. resPonse: We would like to give our thanks to Liu et al. for their interest in our technical note.
The authors mentioned that they fully agreed with our opinion and emphasized that the imaging fusion technique could minimize radiation exposure for doctors and staff, and reduce the use of contrast medium. Additionally, they mentioned the potential of this technique in AVMs.
We also think the technique could have a potential use in the treatment of cerebral AVMs. The 3D MRA-MRI fusion has advantages, such as determination of exact location of the AVM to prevent additional damage during surgical access and to facilitate the procedure, identifying arterial feeders and drainage veins in complex AVMs.
As techniques improve, our ability to use this kind of treatment option, especially in proximal aneurysms, is feasible. The chance of cisternal localization of distal arteries being changed by the microcatheter and guidewire should be kept in mind during navigation. Digital compensation methods are also improving. All dose-reduction techniques in combination with such technology will help and may force us to change our daily practice in the near future. We used a 0° Wolfe endoscope with a mounted rigid suction attachment and channel for intermittent irrigation as described in our papers. As in the technique described by the authors, the suction-mounted endoscope is held in the left hand while the right hand dissects with regular bipolar cautery forceps or resects with an ultrasonic aspirator under endoscopic vision. We had a similar experience with regard to improved magnification, dissection, and illumination. Furthermore, unlike the instrumentation used by the authors, the additional irrigation line in our mounted endoscope facilitated the operative technique.
Through the authors' experience with vestibular neurectomy, they report that improved maneuverability and light intensity from this two-handed endoscopic technique "virtually eliminates" deficiencies of 2D viewing. However, in our experience, using this technique for more complex dissection and tumor resection requires a significant learning curve. Movement and light shadow cues from an endoscope do not provide the same visual depth perception and ease of understanding the structural relationships that a microscope allows for when used for complex dissections. We attached a Stealth probe to the endoscope in our technique for intraoperative guidance to compensate to some degree for the lack of stereoscopic vision.
The single-operator endoscopic technique facilitates procedures performed in a variety of patient positions (for example, supine, prone, lateral, park-bench, sitting) with improved maneuverability and positioning comfort of the operator over the traditional microscope. Difficult-to-access and deep-seated tumors that may be firm, vascular, or attached to critical structures can be safely removed with the improved magnification from the endoscope in combination with the bimanual dexterity achieved with the attachments to the endoscope in the two-handed-technique. We agree that the single-operator, two-handed endoscopic-directed approach is both safe and effective for a variety of procedures. The recent progress made in 3D endoscopic devices may further advance this technique. Traumatic head injury caused a breakdown of the blood-brain barrier and led to the spreading of lymphocytes into brain parenchyma with progression of an inflammatory process in the brain. Sánchez-Aguilar et al. 3 performed a clinical trial to investigate the effect of rosuvastatin on inflammation-related cytokine profiles. They found that rosuvastatin significantly reduced the tumor necrosis factor-α level. Moreover, the treatment with rosuvastatin was correlated with a decrease in disability scores and better functional outcome.
Since rosuvastatin belongs to a family of histone deacetylation inhibitors, it may turn on some inflammation-regulated genes.
1,2 The changes in gene expression profiles are one of the major issues in statin-treated studies that could be addressed in the future.
Tri-Service General Hospital National Defense Medical Center Taipei, Taiwan resPonse: The relevance of immunological phenomena activated after traumatic brain injury is widely recognized in such a way that therapies approaching this target could be promising. 2 Our study of rosuvastatin demonstrated an effect on tumor necrosis factor-α levels and the association between this therapy and a possible reduction in disability. Admittedly, one trial cannot demonstrate all the possible benefits or collateral effects of a new drug's application. Common problems of trauma studies should be considered (sample size, population heterogeneity, and so forth) in the interpretation of our results.
1,4 Moreover, we have measured the cytokine levels in plasma, and so we could be speculating that a measurement in CSF or cerebral tissue would be more exact. 3 Gene expression in brain tissue and regulation of leukocyte cell populations are other aspects to consider. We should not forget that statins act not only as regulators of inflammation but also as promoters of neuroplasticity, antioxidation, and improvements in microcirculation. 8 All of these possible mechanisms could not be easily translated into clinical trials. However, if we considered the experimental and clinical evidence, further clinical trials are urgently needed.
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San Luis Potosí, México J. huMberTo TaPia 1 The authors retrospectively analyzed the MRI and clinical records of 36 patients with traumatic brainstem injury and found that "midline-crossing" bilateral injuries to the pons and medulla are associated with poor outcomes, although 2 patients with midline-crossing ventral pontine lesions both had a functional recovery. In addition, although the authors analyzed the volume of the brainstem lesions, they did not analyze their location or depth.
In our paper, as Dr. Chew mentioned, superficial and ventral brainstem lesions were associated with good outcomes. 5 Even though continuous lesions were observed at the bilateral brainstem, we did not use the term "midlinecrossing" to describe these lesions, because we did not understand the mechanism of injury. If unilateral lesions progress to another side, midline-crossing injury may be an appropriate name; however, concurrent bilateral injuries do not cross but instead are attached to each other. Therefore, we analyzed only unilateral and bilateral injuries.
I believe that brainstem lesion volume is not the only prognostic factor; however, it is reasonable to suspect that larger brainstem lesions will exhibit poorer prognoses than smaller brainstem lesions. In Dr. Chew's results, the total volume of brainstem injury did not correlate with outcome. This result may be attributable to some problems in the study design and confounding factors. In their study, patients who did not recover underwent MRI an average of 0.8 days after admission, whereas those who did recover underwent MRI an average of 4.2 days after admission. The authors reported that on linear regression, lesion size did not vary with the time to scan. The association between time after injury and maximum lesion size depends on various factors. Small lesions may disappear in a few days after injury. The contusion lesion size sometimes increases over a few days after injury as a result of secondary injuries. We cannot know the exact timing of the maximum lesion size without conducting a sequential imaging acquisition study.
We discussed 2 mechanisms of brainstem injury: primary brainstem injury that occurs following direct impact of the brainstem against the tentorial free edge and brainstem injury associated with diffuse axonal injury. 5 Direct focal brainstem injuries caused by an impact against the free tentorial edge have been pathologically and radiologically recognized. [2] [3] [4] It is sometimes difficult to differentiate these 2 mechanisms of injury; however, brainstem lesion size and location and supratentorial lesion findings are helpful. Dr. Chew and colleagues did not discuss the mechanism of brainstem injury. I believe that differentiating these 2 mechanisms of brainstem injury is critical for diagnosing and understanding traumatic brainstem injuries. For instance, KIF14 is a new biomarker with significant prognostic potential. Gliomas tend to demonstrate almost 4 times higher levels of KIF14 than normal brain tissue. More aggressive gliomas tend to express increased KIF14 levels. 7 Low Karnofsky Performance Scale (KPS) scores as well as higher tumor grades are typically seen with increasing KIF14 expression. Upregulation of KIF14 correlates with decreased overall survival and poor clinical outcome.
Similarly, microRNA-375 (miR-375) is another emerg ing biomarker. Gliomas tend to express significantly reduced miR-375 levels in comparison with that in normal brain tissue. Advanced tumor grade is typically seen in gliomas with low miR-375 expression. 1 In fact, the miR-375 lev el is a significant parameter influencing overall patient sur vival. Another new biomarker is ELTD1. For instance, low-grade gliomas express relatively less ELTD1 than do high-grade gliomas. 4 Moreover, ELTD1 expression bears a sig nificant effect on tumor outcome and overall prognosis. An other emerging biomarker of gliomas is SPARC-like pro tein 1. A close relationship exists between tumor grade and SPARC-like protein 1 expression by the glioma. 5 Similarly, recent data suggest that a poor clinical outcome is to be expected in gliomas that co-express matrix metalloproteinase (MMP)-14 and MMP-19. The MMP-14 and MMP-19 levels are typically much higher in gliomas than in normal brain tissue. Low KPS scores are typically seen with either MMP-14 or MMP-19 expression. Individual elevations in MMP-14 or MMP-19 indicate a poor clinical prognosis, which is made worse when both proteins are co-expressed. 6 Another emerging marker of gliomas is SATB1. Expression of SATB1 is seen in nearly 63% of all gliomas. More aggressive gliomas tend to express higher SATB1 levels. Not surprisingly, a poor clinical outcome is seen in patients with gliomas that demonstrate high SATB1 levels. 2 A positive correlation has been seen between SATB1 expression and Ki 67 expression in gliomas.
The above discussion clearly highlights the emerging diagnostic as well as prognostic markers of gliomas. Hopefully, the next few years will see the increased use of these biomarkers for better management and treatment of gliomas.
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resPonse: We appreciate Dr. Kapoor's interest in our paper. We examined the expression of CNTFRα and its association with glioma grade and tumor-initiating cells and found that increased CNTFRα expression correlates with tumor grade and is increased in tumor-initiating cells. These findings indicate that CNTFRα expression may have a role in determining clinical grade of gliomas and has a role in tumor-initiating cell maintenance. Because of its expression and role in glioma-initiating cells, CNTFRα represents an attractive therapeutic target for malignant gliomas.
Like CNTFRα, other potential biological markers are associated with glioma grade and survival. These markers have been identified to describe the molecular features of malignant gliomas. Similarly, we describe CNTFRα not only as a marker associated with tumor grade, but also as a marker defining the subset of gliomainitiating cells. It is this subset of glioma cells that may underlie the refractory nature of malignant gliomas to currently available therapeutics. [1] [2] [3] Consequently, identification of unique tu mor-initiating cell markers, including CNTFRα, provides additional and deeper insight into the biology of malignant gliomas, as well as an attractive target for new putative therapeutics. 
